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obese patients with T2DM. Cost-effectiveness (INR/unit of effective-
ness) varied from 3.7 to 45.2. Seventeen percent of the patients with 
T2DM included in this study received less cost-effective antidiabetic 
drugs.
Conclusions: Prescriptions of cost-effective antidiabetic drugs (83%) 
were more common than less cost-effective antidiabetic drugs (17%) 
in patients with T2DM from Mumbai, India.
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Background: Immunization is the most cost-effective intervention 
for infectious diseases, which are the major cause of morbidity and 
mortality worldwide. Vaccines not only protect the individual who 
is vaccinated but also reduce the burden of infectious vaccine-pre-
ventable diseases for the entire community.1 Adult vaccination is very 
important given that > 25% of mortality is due to infectious diseases.2 
There is a scarcity of information on the vaccination status of young 
adults and the role of socioeconomic conditions in India.
Objectives: The present study explored the adult vaccination status 
and influence of income and education of parents on adult vaccina-
tion status in university students from Mumbai, India.
Methods: This descriptive study was performed from January to 
April 2015 among undergraduate pharmacy students from Mumbai 
University, India, by using a validated study questionnaire. Students 
were contacted by a study team member in their classrooms and were 
given a brief introduction about the research project. Those who 
desired to participate in the study were explained the purpose and 
objectives of the study. On the basis of the eligibility criteria (those 
who gave written informed consent and were between the age group 
of 18–25 years), 149 students were selected for the present study. 
A total of 8 vaccines (namely, Tdap/DTP, varicella, measles-mumps-
rubella [MMR], influenza, pneumococcal, hepatitis A, hepatitis B, 
and meningococcal) were included in this study for all the respond-
ents. In addition to these vaccines, human papillomavirus (HPV) 
vaccine was also included for female respondents.
Results: There were total of 149 (75 males and 74 females) respond-
ents with a mean age of 21.5 years. The top 3 immunizations were 
Td/Tdap (97.3%), MMR (66.4%), and hepatitis B (55%) among the 
respondents. Only 4 (5.5%) female respondents had been immunized 
against HPV. The lowest income group (< 50,000 INR/month) had 
the least vaccination coverage for all the vaccines, except for MMR 
and HPV. Vaccination coverage was lesser for respondents with par-
ent’s education below a high school than those with parent’s edu-
cation of graduation and above, except for pneumococcal vaccine.
Conclusions: India’s National Centre for Disease Control has recom-
mended Td/Tdap, MMR, and varicella for all adults and influenza, 
pneumococci, hepatitis A, hepatitis B, meningococcal, and HPV for 
adults with certain risk factors. Td/Tdap (97.3%) and MMR (66.4%) 
coverage was in line with the recommendations. For all the other 
vaccines, the coverage was low, varying from 5.5% to 35.4%. The 
vaccination coverage was better in respondents with higher educated 
and higher income parents. We suggest that patient education, plan-
ning by government for the implementation of a policy for adult 
vaccination, and involvement of physicians are needed for better 
adult vaccination coverage.
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Our species may plausibly boast that, in the relatively short period 
since it first emerged, it has enormously advanced in knowledge, 
science, and technical progress. When it comes to our moral develop-
ment, however, the distance we have covered is comparatively negligi-
ble. As a result, man today resembles a mighty giant who has no clue 
how to use his powers; and just like a child playing with grenades, 
man has become utterly dangerous to himself, to other species, and 
to the globe in general. The situation is bound to steadily deteriorate 
as long as the gap between our powers and our morality continues 
to increase. What if, however, we could medically accelerate our 
moral development? Even better, what if we could one and for all 
render our species totally immune to certain vices? The advances in 
biomedicine nowadays seem to hold such a promise. In this essay, 
I will discuss the prospect of medically intervening with the moral 
disposition of humans in such a way as to even eliminate morally 
unjustifiable choices. I will claim that such an intervention would 
not necessarily compromise either the free will or the autonomy of 
moral agents. To support my view, I will provide a set of arguments 
based on the Kantian tradition in ethics, since the opponents of moral 
enhancement mostly evoke arguments that focus on autonomy and 
free will. I will conclude with the view that moral enhancement by 
means of pharmaceutical intervention might even be a perfect duty 
for moral agents in the light of Kantian ethics.
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enhancement, utilitarianism.
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Background: Many clinical trials, including those performed in the 
developing world, are designed and conducted by academics without 
pharmaceutical sponsorship, input, or supervision. Although many 
academics are adept at asking and answering basic scientific ques-
tions, unfortunately few academic institutions or investigators are 
equipped to provide the same quality of clinical trial design, conduct, 
and oversight as those done by the pharmaceutical industry.
